Olema Pharmaceuticals (NASDAQ:OLMA) Rating Reiterated by Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Olema Pharmaceuticals (NASDAQ:OLMA – Free Report) in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a $21.00 target price on the stock. Other research analysts have also recently issued research reports about the company. Capital One Financial increased their target price on […]

Related Keywords

Canada ,California ,United States ,Cyrus Harmon ,Royal Bank ,News Ratings For Olema Pharmaceuticals Daily ,Olema Pharmaceuticals Company Profile ,Analyst Recommendations For Olema Pharmaceuticals ,Wells Fargo Company ,Olema Pharmaceuticals Stock Performance ,Olema Pharmaceuticals ,Credit Suisse Group ,Ep Wealth Advisors ,Olema Pharmaceuticals Inc ,Institutional Trading Of Olema Pharmaceuticals ,Jpmorgan Chase Co ,Citigroup Inc ,Free Report ,One Financial ,Suisse Group ,Get Free Report ,Director Cyrus Harmon ,State Teachers Retirement System ,Wells Fargo ,Olema Pharmaceuticals Daily ,Nasdaq Olma ,Dolma ,Medical ,Reiterated Rating ,Oppenheimer Holdings Inc ,